浙江莎普爱思药业股份有限公司 关于获得去氧肾上腺素酮咯酸溶液临床试验批准通知书的公告

Group 1 - The company has received approval from the National Medical Products Administration for the clinical trial of Deoxycorticosterone Ketone Acid Solution, which is intended for use in maintaining mydriasis during cataract surgery or artificial lens replacement surgery [1][2] - The drug is classified as a Class 3 chemical drug and is an eye preparation [1] - The total research and development investment for the Deoxycorticosterone Ketone Acid Solution project has reached approximately 5.5563 million RMB [3]